Format

Send to

Choose Destination
Cancer Lett. 2014 Sep 1;351(2):215-21. doi: 10.1016/j.canlet.2014.05.020. Epub 2014 Jun 2.

Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance.

Author information

1
Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Japan.
2
Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Japan. Electronic address: sakamotohrs@chugai-pharm.co.jp.

Abstract

The clinical efficacy of the ALK inhibitor crizotinib has been demonstrated in ALK fusion-positive NSCLC; however, resistance to crizotinib certainly occurs through ALK secondary mutations in clinical use. Here we examined the efficacy of a selective ALK inhibitor alectinib/CH5424802 in models of crizotinib resistance. Alectinib led to tumor size reduction in EML4-ALK-positive xenograft tumors that failed to regress fully during the treatment with crizotinib. In addition, alectinib inhibited the growth of some EML4-ALK mutant-driven tumors, including the G1269A model. These results demonstrated that alectinib might provide therapeutic opportunities for crizotinib-treated patients with ALK secondary mutations.

KEYWORDS:

ALK; ALK inhibitor; Alectinib; Drug resistance; NSCLC; Xenograft model

PMID:
24887559
DOI:
10.1016/j.canlet.2014.05.020
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center